James Samuel Shannon

CIK: 0001485417

Transaction Breakdown

Open Market Buys (P)3 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

XLO

Xilio Therapeutics, Inc.

Director

MNKD

MANNKIND CORP

Director

PRQR

ProQR Therapeutics N.V.

Director

Discretionary Trading P&L

Holdings

Transaction History (9 total)

XLO
Xilio Therapeutics, Inc.
Jun 11, 2026
Award(A)
Stock Option (right to buy)
Direct
5K shares-
MNKD
MANNKIND CORP
May 20, 2026
Award(A)
Restricted Stock Unit
Direct
82.8K shares-
MNKD
MANNKIND CORP
May 20, 2026
Award(A)
Restricted Stock Unit
Direct
16.6K shares-
XLO
Xilio Therapeutics, Inc.
Mar 26, 2026
Purchase(P)
Direct
5K shares at avg. $8.79$44K
MNKD
MANNKIND CORP
Mar 1, 2026
Award(A)
Direct
12K shares at avg. $3.27$39K
XLO
Xilio Therapeutics, Inc.
Jun 17, 2025
Purchase(P)
Direct
25K shares at avg. $0.69$17K
XLO
Xilio Therapeutics, Inc.
Jun 16, 2025
Purchase(P)
Direct
45K shares at avg. $0.69$31K
XLO
Xilio Therapeutics, Inc.
Jun 11, 2025
Award(A)
Stock Option (right to buy)
Direct
31K shares-
MNKD
MANNKIND CORP
May 14, 2025
Award(A)
Restricted Stock Unit
Direct
52.9K shares-

		Type	Shares	Price		Ownership
Jun 11, 2026	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	5,000	-	-	Direct
May 20, 2026	MNKD MANNKIND CORP	Award(A) Restricted Stock Unit	82,781	-	-	Direct
May 20, 2026	MNKD MANNKIND CORP	Award(A) Restricted Stock Unit	16,556	-	-	Direct
Mar 26, 2026	XLO Xilio Therapeutics, Inc.	Purchase(P)	5,000	$8.79	$43,950	Direct
Mar 1, 2026	MNKD MANNKIND CORP	Award(A)	12,000	$3.27	$39,240	Direct
Jun 17, 2025	XLO Xilio Therapeutics, Inc.	Purchase(P)	25,000	$0.69	$17,215	Direct
Jun 16, 2025	XLO Xilio Therapeutics, Inc.	Purchase(P)	45,000	$0.69	$30,870	Direct
Jun 11, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	31,000	-	-	Direct
May 14, 2025	MNKD MANNKIND CORP	Award(A) Restricted Stock Unit	52,854	-	-	Direct

1-9 of 9 transactions

About Shannon James Samuel

Shannon James Samuel (SEC CIK 0001485417) files insider reports with the SEC as Director of Xilio Therapeutics, Inc. (XLO), Director of MANNKIND CORP (MNKD) and Director of ProQR Therapeutics N.V. (PRQR).

Signal8 holds 8 ownership filings by Shannon James Samuel (1 Form 3, 7 Form 4), filed between May 16, 2025 and Jun 12, 2026. Those filings report 9 transactions, from May 14, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Shannon James Samuel's filings is in WALTHAM, MA.

Recent filings by Shannon James Samuel

Jun 11, 2026: Grant or award of XLO derivative securities (Form 4, code A).
May 20, 2026: Grants or awards of MNKD derivative securities (2 lines, Form 4, code A).
Mar 26, 2026: Open-market purchase of XLO shares (Form 4, code P).
Mar 1, 2026: Grant or award of MNKD shares (Form 4, code A).
Jun 17, 2025: Open-market purchase of XLO shares (Form 4, code P).

Other insiders filing for Xilio Therapeutics, Inc. (XLO)

Houvras Yariv, CHIEF MEDICAL OFFICER
Bello Akintunde Olatokumbo, Director
Curran Daniel J., Director
Xu Yuan, Director
ROSS ROBERT W., Director
Bonstein Sara, Director

How to read Form 4 transaction codes